At a glance
ClinicalIndex Comparison RecordN/ACompleted· 4,876 enrolled
Drug / intervention
OAD +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Post Marketing Surveillance on Long Term Drug Use of Trazenta® Tablets in Patients With Type 2 Diabetes Mellitus
In Brief
An observational study evaluating OAD and Trazenta for Diabetes Mellitus, Type 2. Completed, enrolled 4,876 participants across 1 site.
Detailed Summary
Study to investigate the safety and efficacy of long-term daily use of Trazenta® Tablets as monotherapy in patients with type 2 diabetes mellitus and to assess baseline characteristics of patients with type 2 diabetes mellitus starting Trazenta® Tablets or any other oral antidiabetic monotherapy (naïve or switched from prior therapy of different oral antidiabetic drug).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesJapan
CollaboratorsEli Lilly and Company
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2012
First PostedJul 2012
Primary CompletionSep 2017
Study CompletionSep 2017
TodayJul 2026
First PostedJul 26, 2012
Enrollment StartJul 23, 2012
Primary CompletionSep 5, 2017
Study CompletionSep 14, 2017
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 13.9 years ago
Interventions
OADdrug
OAD except Trazenta tablets
Trazentadrug
Linagliptin